JSC SCRI Holdings LLC, through its subsidiary Sarah Cannon Research Institute (SCRI), is a leading oncology research organization dedicated to advancing cancer treatments and improving patient outcomes globally. With a mission-driven approach, SCRI focuses on community-based clinical trials and has conducted over 750 first-in-human trials, contributing significantly to the development of new cancer therapies approved by the FDA. The organization collaborates with a vast network of over 1,300 physicians across more than 250 locations in 24 states, emphasizing innovative research and personalized care. As part of McKesson, a Fortune 10 company, SCRI is committed to fostering a diverse and inclusive workplace, offering comprehensive benefits and a competitive compensation package to support the well-being of its employees and the communities it serves.